Activation of angiotensin type 2 (AT2) receptors prevents myocardial hypertrophy in Zucker diabetic fatty rats

AimsCompound 21 (C21), selective AT2 receptor agonist, has cardioprotective effects in experimental models of hypertension and myocardial infarction. The aims of the study was to evaluate the effect of C21, losartan, or both in Zucker diabetic fatty (ZDF) rats (type 2 diabetes) on (1) the prevention of myocardial hypertrophy; (2) myocardial expression of phosphatase and tensin homolog (PTEN), a target gene of miR-30a-3p, involved in myocardial remodelling.MethodsExperiments were performed in ZDF (n=33) and in control Lean (8) rats. From the 6th to the 20th week of age, we administered C21 (0.3mg/kg/day) to 8 ZDF rats. 8 ZDF rats were treated with losartan (10mg/kg/day), 8 rats underwent combination treatment, C21+losartan, and 9 ZDF rats were left untreated. Blood glucose and blood pressure were measured every 4weeks. At the end of the study the hearts were removed, the apex was cut for the quantification of PTEN mRNA and miR-30a-3p expression (realtime-PCR). Myocardial hypertrophy was evaluated by histomorphometric analysis, and nitrotyrosine expression (as marker of oxidative stress) by immunohistochemistry.ResultsZDF rats had higher blood glucose (p<0.0001) with respect to control Lean rats, while blood pressure did not change. Both parameters were not modified by C21 treatment, while losartan and losartan+C21 reduced blood pressure in ZDF rats (p<0.05). miR-30a-3p expression was increased in ZDF rats (p<0.01) and PTEN mRNA expression was decreased (p<0.05). ZDF rats developed myocardial hypertrophy (p<0.01) and increased oxidative stress (p<0.01), both were prevented by C21 or losartan, or combination treatment. C21 or losartan normalized the expression of miR-30a-3p and PTEN.ConclusionsActivation of AT2 receptors or AT1 receptor blockade prevents the development of myocardial hypertrophy in ZDF rats. This occurs through the modulation of the miR-30a-3p/PTEN interaction.